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tional research and clinical trials. These results contribute to a
better understanding of how QOL issues are perceived by head
and neck patients in India, strengthening the cross-cultural com-
parability of this instrument.
PCN50
CHALLENGES AND LIMITATIONS OF IDENTIFYING
PRESCRIPTION TREATMENT PATTERNS FOR PATIENTS WITH
METASTATIC BREAST CANCER USING COMMERCIALLY
INSURED CLAIMS DATABASES
Harris LA,Yu Y, Donato B
Bristol-Myers Squibb, Wallingford, CT, USA
OBJECTIVES: The objective of this study was to illustrate the
challenges and limitations of using claims data and developing
algorithms to study prescription patterns for metastatic breast
cancer (MBC) in patients previously treated with anthracycline
and taxane. METHODS: Extract from the PharMetrics Inte-
grated Outcomes Database between Janaury 1999 and June
2005 was used. Lacking a diagnosis code for MBC, we deﬁned
the condition = 2 ICD-9 codes for breast cancer (BC) and 1 ICD-
9 code for distant metastases. Drug exposure was deﬁned as °Y´1
NDC/J-code for anthracycline and taxane. A treatment interval
of 21 days was created to account for a high proportion of
missing or zero values for days supply of chemotherapy agents
recorded in claims database and to determine treatment duration
assigned to all agents from reference date, deﬁned as the dispense
date of the ﬁrst anthracycline or taxane prescription, whichever
occurred later. Consecutive intervals with same agents were col-
lapsed into one regimen regardless of sequence; otherwise inter-
vals were treated as separate regimens. RESULTS: Among
38,588 patients with °Y´2 BC diagnoses, 5017 (13%) exhibited
°Y´1 diagnoses for distant metastasis, 1121 (3%) were previously
exposed to an anthracycline and a taxane, and 1028 met other
criteria (age°Y´18 years and eligibility °Y´6 months). Of the 1028,
67% did not receive sequential therapy, and 80% of these had
non-chemotherapy claims 90 days following last chemotherapy,
with a mean post chemotherapy duration of 489 ± 430 days.
Among the 33% who received sequential therapy, the mean
number of sequential therapies was 2.8 ± 2.7 with mean dura-
tion of 66 ± 82 days. CONCLUSION: The current analysis illus-
trates a method of using algorithms to deﬁne MBC diagnoses
and treatment duration in claims-based treatment pattern
studies. However, such algorithms must be validated against the
patients’ medical records in order to assess the respective accu-
racy of disease and treatment pattern identiﬁcation.
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OBJECTIVES: eVOBS is an international, non-interventional,
observational study of clinical and economic outcomes in
patients who receive VELCADE for the approved indication in
multiple myeloma. METHODS: Patients who initiate VELCADE
therapy for the approved indication are eligible for the study.
Retrospective treatment data from 12 months prior to study
entry and prospective treatment data for 36 months are collected
via a secure, privacy-protected website. At study entry, submit-
ted data are electronically screened against validation rules that
have been prospectively established in consultation with multi-
ple myeloma treatment specialists and data analysis specialists.
These rules were designed to prevent missing data, duplicate data
and data outside pre-established, logical ranges. Initial inputs
require study center conﬁrmation before the system uploads data
to the central database. During the study, if there is any data that
is inconsistent with previously submitted entries, study sites
submit corrections via an audited online data change request
system. Finally, an ongoing audit process is used to validate the
quality of the data uploaded to the central database. This process
uses monthly reports to identify potential inconsistencies within
the dataset after data has been validated at entry. RESULTS:
Uploaded data undergoes quality control checks, requiring
adjustment by physicians to be minimal. Audit reports help to
redress data entry training issues, further enhancing data accu-
racy. Analysis is only conducted on patients after resolution of
outstanding supplemental data queries. CONCLUSION: The
goal of this study is document outcomes in a generalizable, rep-
resentative patient cohort. This information will broaden our
understanding of the use of VELCADE in typical clinical prac-
tice, outside of the interventional clinical trial setting. This
largely automated three-stage quality control process streamlines
the implementation of this non-interventional, observational
research and permits the inclusion of patients from a broad geo-
graphic region. The study method allows for faster analysis and
presentation of robust, pragmatic outcomes data.
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OBJECTIVES: To compare the impact of 11 types of cancer on
different domains of HRQL using the FACT-G and EQ-VAS.
METHODS: Patients diagnosed with advanced cancer of the
bladder, brain, breast, colorectal, head/neck, hepatobiliary/pan-
creas, kidney, lung, lymphoma, ovary or prostate completed
HRQL assessments. HRQL was compared between patient
groups for each subscale of the FACT-G, i.e., physical well-being
(PWB), social/family wellbeing (SWB), emotional well-being
(EWB) and functional well-being (FWB), and EQ-VAS, unad-
justed and adjusted for age/gender using regression models.
RESULTS: Approximately 50 patients were recruited for each
cancer group (total n = 534). Mean age (SD) ranged from 52(11)
(brain) to 70(8) (prostate). Unadjusted mean (SD) scores 
for PWB ranged from 66.8(17.2) (head/neck) to 78.1(21.3)
(prostate); for SWB ranged from 81.4(19.1) (brain) to 90.6(22.0)
(kidney); for EWB ranged from 61.7(16.0) (breast) to 72.0(16.9)
(prostate); and FWB ranged from 54.7(20.2) (head/neck) to
67.8(18.5) (prostate). EQ-5D VAS mean scores were lowest for
head/neck [61.8(21.7)] and highest for colorectal [72.0(17.1)].
Compared to lymphoma, adjusting for age/gender, PWB mean
scores (SE) were signiﬁcantly lower for patients with head/neck
[−10.9(4.0)], hepatobiliary [−10.9(4.0)], and kidney [−9.7(4.0)].
FWB mean scores were signiﬁcantly lower for head/neck 
[−10(3.2)], hepatobiliary [−8.9(3.1)], bladder [−7.7(3.6)], and
lung [−6.7(3.1)]. Patients 65 years and older had mean (SE)
scores for PWB = +9.2(2.1), EWB = +2.9(1.0), FWB = +3.1(1.6),
and EQ VAS = +4.5(2.1) compared to patients aged 45 to 64.
For median rank across all FACT subscales, hepatobiliary ranked
worst and prostate the highest. Adjusting for age and gender,
hepatobiliary ranked worst and lymphoma highest based on
FACT median scores, while breast ranked lowest and colorectal
highest based on mean VAS scores. CONCLUSION: Older
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cancer patients generally report greater well-being across all
domains, but age-adjusted results suggest hepatobiliary and
head/neck cancer have signiﬁcantly worse HRQL among differ-
ent types of cancer, particularly in terms of PWB and FWB.
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OBJECTIVES: To evaluate brain cancer speciﬁc health related
quality-of-life (HRQOL) instruments used in glioblastoma mul-
tiforme (GBM) patients for group and individual level decision-
making. METHODS: An extensive literature search was
conducted to identify brain cancer speciﬁc HRQOL instruments
using several databases including Medline, PsycINFO, and
Health and Psychosocial Instruments. Key search terms included
“quality of life” and “glioblastoma”. Only brain cancer speciﬁc
HRQOL instruments evaluating GBM patients were retained for
evaluation of item information, practicality, breadth, depth, reli-
ability (group level based on Nunnally & Bernstein 1994 and
individual level based on McHorney & Tarlov 1995 criteria),
validity and responsiveness. RESULTS: Four instruments were
identiﬁed: extended Rotterdam Symptom Checklist (e-RSCL);
European Organization for Research and Treatment of Cancer
quality-of-life core 30 (EORTC QLQ C30) with brain cancer
module (BCM20); EORTC QLQ C30+3 with BCM20; and a
newly developed instrument deriving its core from the Sickness
Impact Proﬁle (SIP) with addition of a brain cancer module (BC).
The EORTC QLQ C30 was the most widely used instrument
and satisﬁed practicality, breadth and validity criteria (conver-
gent: r = 0.61–0.70, p < 0.05; known-groups: p < 0.05). This
instrument offered the most extensive reliability information
with 4 of 9 domains meeting the 0.70 criterion for group level
decision-making. The SIP core with BC was notable for high
levels of missing psychometric data. CONCLUSION: Measuring
the impact of treatment on HRQOL is critical, especially in ter-
minal conditions. However, none of the instruments in this study
met the criteria for individual level decision-making. This was
due in part to unavailable psychometric data as well as data not
meeting study criteria. Based on the results from this study, the
EORTC QLQ C30 is recommended for use in group level deci-
sion-making in conjunction with another HRQOL instrument,
for example a generic instrument. Further studies are required to
evaluate the psychometric properties of the BCM20.
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OBJECTIVES: To assess health-related quality of life (HRQOL)
in patients with metastatic renal cell carcinoma (mRCC) treated
with axitinib (AG-013736), a potent vascular endothelial growth
factor receptor inhibitor. METHODS: In a single-arm phase II
trial, mRCC patients who had received one prior cytokine-based
therapy were treated with axitinib 5 mg orally BID until disease
progression or no response (46% of patients had a PR, and 40%
had stable disease). HRQOL, a secondary endpoint, was mea-
sured using the European Organization for the Research and
Treatment of Cancer Quality of Life Questionnaire-Core 30
(EORTC-QLQ-C30). The QLQ-C30 consists of 30 questions,
rated on a 0–4 scale, measuring functional status, symptoms, and
global health. Higher scores on the functional status and global
health scales reﬂect better HRQOL, whereas higher scores on the
symptom scales indicate more severe symptoms. QLQ-C30 was
completed at baseline, monthly for the ﬁrst two cycles, every 2
cycles thereafter, and at follow-up. Longitudinal analyses were
used to evaluate HRQOL data through 36 cycles of treatment.
RESULTS: Fifty-four patients completed baseline HRQOL
assessments. Statistically signiﬁcant changes (P < 0.05) were
observed in average scores from baseline to post-treatment in the
role, cognitive and social functioning scales, and the nausea/vom-
iting, pain and diarrhea symptoms. These changes were approx-
imately <1/4 of a response category. The exception was diarrhea,
with a 1/2 category change, which equated to a change from
“no” to “a little” diarrhea. CONCLUSION: Although some
measures of functioning and symptoms are statistically signiﬁ-
cant, interpretation of QLQ-C30 scores from the current litera-
ture (King 1996 Qual Life Res; Osoba 1998 JCO) indicate that
changes observed in the study are, overall, too small to reﬂect a
palpable change in patient functioning and symptoms. Thus,
treatment with axitinib demonstrated minimal disruptions in
HRQOL compared to baseline levels in mRCC patients.
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OBJECTIVES: HUI is a family of multi-attribute, health-status
classiﬁcation and preference scoring systems for general popula-
tion health surveys and clinical research studies including cost-
utility economic evaluations of alternative treatments. It has been
translated and culturally adapted into many languages. This is
the ﬁrst report of HUI in Turkish. METHODS: The original
English-language health-status classiﬁcation system was trans-
lated into Turkish by 3 physicians from the pediatric oncology
clinic in Istanbul. The consensus forward translation was inde-
pendently back translated and then reviewed by HUInc staff. It
provides the keywords for subsequent HUI questionnaire trans-
lation. The same forward/backward translation strategy with 
all-party consensus produced the interviewer-administered 
questionnaire for proxy assessments (HUI23P1Tr.40Q). The
questionnaire was evaluated for acceptability and construct
validity by interviewing parents of patients who developed neu-
tropenia during their ﬁrst chemotherapy cycle. Parents were
interviewed twice at the Istanbul clinic, during and again after
the neutropenic episode. Upon completion of the ﬁrst interview,
parents were asked informally about the questionnaire readabil-
ity and suitability. Utility scores are from the original published
functions based on general population preference measurements
and differences in mean utility scores were tested using ANOVA.
RESULTS: Parents of 50 newly diagnosed patients (26 males,
mean age 91.3 months) were interviewed. The questionnaire was
reported by all parents to be understandable and acceptable.
Overall utility scores of health-related quality of life (HRQL)
during neutropenic episodes (HUI2 mean = 0.65, SD = 0.251;
HUI3 mean = 0.60, SD = 0.328) were signiﬁcantly and impor-
tantly lower (HUI2 p = 0.008, HUI3 p = 0.034) than after recov-
ery (HUI2 mean = 0.79, SD = 0.244; HUI3 mean = 0.75, SD =
0.315) as were the single-attribute scores for HUI2 and HUI3
